Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;95:63-68

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santos, M. T.
Right arrow Articles by Safier, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santos, M. T.
Right arrow Articles by Safier, L. B.

(Circulation. 1997;95:63-68.)
© 1997 American Heart Association, Inc.


Articles

Prothrombotic Effects of Erythrocytes on Platelet Reactivity

Reduction by Aspirin

M. Teresa Santos, PhD; Juana Valles, PhD; Justo Aznar, MD; Aaron J. Marcus, MD; M. Johan Broekman, PhD; Lenore B. Safier, MS

the Research Center and Department of Clinical Pathology, University Hospital La Fe, Valencia, Spain (M.T.S., J.V., J.A.), and the Divisions of Hematology and Medical Oncology and Departments of Medicine, Veterans Affairs Medical Center and Cornell University Medical College, New York, NY (A.J.M., M.J.B., L.B.S.).

Correspondence to Aaron J. Marcus, MD, Thrombosis Research Laboratory, Room 13028W, Department of Veterans Affairs Medical Center, 423 E 23rd St, New York, NY 10010-5050. E-mail mjbroek@mail.med.cornell.edu.

Background Aspirin effectively reduces the incidence of secondary vascular occlusive events in only 25% of patients. Low-dose aspirin as currently used blocks platelet production of prothrombotic thromboxane A2 and allows endothelial synthesis of antithrombotic prostacyclin. This regimen minimizes gastrointestinal toxicity. We previously showed that intact erythrocytes markedly enhance platelet reactivity. Therefore we investigated whether supplementation of low-dose aspirin with a single high dose at 2-week intervals could more effectively block erythrocyte promotion of platelet reactivity.

Methods and Results Effects of different aspirin regimens on erythrocyte enhancement of platelet reactivity in normal volunteers were measured with the use of an assay that evaluates both platelet activation and recruitment. After 15 days of daily ingestion of 50 mg aspirin, reactivity of platelets alone was inhibited. However, erythrocyte promotion of platelet activation and recruitment was only inhibited by {approx}50% and persisted in the total absence of thromboxane synthesis. In contrast, if 50 mg/d aspirin was preceded by a single loading dose of 500 mg aspirin, the erythrocyte prothrombotic effect was strongly inhibited ({approx}90%) for 2 to 3 weeks. However, over time, erythrocytes "escaped" from this inhibition, and once again became prothrombotic, even on a daily regimen of 50 mg aspirin.

Conclusions For clinical purposes, we recommend a loading dose of aspirin (500 mg), followed by daily administration of 50 mg. The loading dose should be repeated at 2-week intervals. This regimen blocks recovery of the erythrocyte capacity to promote platelet reactivity and may amplify the therapeutic potential of aspirin in cardiovascular disease.


Key Words: aspirin • platelets • thromboxane • thrombosis • erythrocytes • cardiovascular diseases




This article has been cited by other articles:


Home page
ChestHome page
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 199S - 233S.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
J.-F. Hardy, P. de Moerloose, C. M. Samama, and Members of the Groupe d'Interet en Hemostase Perio
Massive transfusion and coagulopathy: pathophysiology and implications for clinical management: [Transfusion massive et coagulopathie-: physiopathologie et implications cliniques].
Can J Anesth, June 1, 2006; 53(6_suppl): S40 - S58.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. O. Maree, R. J. Curtin, M. Dooley, R. M. Conroy, P. Crean, D. Cox, and D. J. Fitzgerald
Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1258 - 1263.
[Abstract] [Full Text] [PDF]


Home page
ASH ANNUAL MEETING ABSTRACTSHome page
M. T. Santos, J. Valles, M. P. Fuset, F. Perez, A. Moscardo, J. Aznar, and M. Ruano
Aspirin Down-Regulation of Platelet Reactivity in Patients with Acute Coronary Syndrome: Effects of Erythrocytes.
Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1865 - 1865.
[Abstract]


Home page
ChestHome page
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 234S - 264S.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. Houel, E. Mazoyer, B. Boval, M. Kirsch, E. Vermes, L. Drouet, and D. Y. Loisance
Platelet activation and aggregation profile in prolonged external ventricular support
J. Thorac. Cardiovasc. Surg., August 1, 2004; 128(2): 197 - 202.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
J.-F. Hardy, P. de Moerloose, M. Samama, and members of the Groupe d'interet en Hemostase Perio
Massive transfusion and coagulopathy: pathophysiology and implications for clinical management: [Transfusion massive et coagulopathie : physiopathologie et implications cliniques]
Can J Anesth, April 1, 2004; 51(4): 293 - 310.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Valles, M. T. Santos, J. Aznar, M. Martinez, A. Moscardo, M. Pinon, M. J. Broekman, and A. J. Marcus
Platelet-erythrocyte interactions enhance alpha IIbbeta 3 integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo
Blood, May 13, 2002; 99(11): 3978 - 3984.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
F Burdan
Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats
Human and Experimental Toxicology, January 1, 2002; 21(1): 25 - 31.
[Abstract] [PDF]


Home page
ChestHome page
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth
Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Chest, January 1, 2001; 119(1_suppl): 39S - 63S.
[Full Text] [PDF]


Home page
CirculationHome page
M. T. Santos, A. Moscardo, J. Valles, M. Martinez, M. Pinon, J. Aznar, M. J. Broekman, and A. J. Marcus
Participation of Tyrosine Phosphorylation in Cytoskeletal Reorganization, {alpha}IIb{beta}3 Integrin Receptor Activation, and Aspirin-Insensitive Mechanisms of Thrombin-Stimulated Human Platelets
Circulation, October 17, 2000; 102(16): 1924 - 1930.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
R J Gryglewski, W Uracz, and J Swies
Unusual effects of aspirin on ticlopidine induced thrombolysis
Thorax, October 1, 2000; 55(90002): 17S - 19.
[Full Text]


Home page
CLIN APPL THROMB HEMOSTHome page
R. Altman, A. Scazziota, J. Rouvier, and C. Gonzalez
Effects of Ticlopidine or Ticlopidine Plus Aspirin on Platelet Aggregation and ATP Release in Normal Volunteers: Why Aspirin Improves Ticlopidine Antiplatelet Activity
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 243 - 246.
[Abstract] [PDF]


Home page
CirculationHome page
N. Li, N. H. Wallen, and P. Hjemdahl
Evidence for Prothrombotic Effects of Exercise and Limited Protection by Aspirin
Circulation, September 28, 1999; 100(13): 1374 - 1379.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Pratico, M. Pasin, O. P. Barry, A. Ghiselli, G. Sabatino, L. Iuliano, G. A. FitzGerald, and F. Violi
Iron-Dependent Human Platelet Activation and Hydroxyl Radical Formation : Involvement of Protein Kinase C
Circulation, June 22, 1999; 99(24): 3118 - 3124.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Valles, M. T. Santos, J. Aznar, A. Osa, A. Lago, J. Cosin, E. Sanchez, M. J. Broekman, and A. J. Marcus
Erythrocyte Promotion of Platelet Reactivity Decreases the Effectiveness of Aspirin as an Antithrombotic Therapeutic Modality : The Effect of Low-Dose Aspirin Is Less Than Optimal in Patients With Vascular Disease Due to Prothrombotic Effects of Erythrocytes on Platelet Reactivity
Circulation, February 3, 1998; 97(4): 350 - 355.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. R. Pawloski, R. V. Swaminathan, and J. S. Stamler
Cell-Free and Erythrocytic S-Nitrosohemoglobin Inhibits Human Platelet Aggregation
Circulation, January 27, 1998; 97(3): 263 - 267.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. S. Coller
Monitoring Platelet GP IIb/IIIa Antagonist Therapy
Circulation, January 13, 1998; 97(1): 5 - 9.
[Full Text] [PDF]


Home page
CirculationHome page
R. Altman, A. Scazziota, J. Rouvier, M. T. Santos, J. Valles, J. Aznar, A. J. Marcus, and M. J. Broekman
Daily 50 mg or 500 mg Aspirin Does Not Affect the Cooperation of Arachidonic Acid and ADP on Platelet Aggregation • Response
Circulation, January 13, 1998; 97(1): 118 - 119.
[Full Text]


Home page
CirculationHome page
B. Rocca and G. A. FitzGerald
Simply Read: Erythrocytes Modulate Platelet Function: Should We Rethink the Way We Give Aspirin?
Circulation, January 7, 1997; 95(1): 11 - 13.
[Full Text]